NeoGenomics NEO Client direct billing — NET REVENUE
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by NeoGenomics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax.
The official record: NeoGenomics’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about NeoGenomics's client direct billing — net revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NeoGenomics's client direct billing — NET REVENUE?
- NeoGenomics (NEO) reported client direct billing — NET REVENUE of $131.61M in Q1 2026.
- How has NeoGenomics's client direct billing — NET REVENUE changed year-over-year?
- NeoGenomics's client direct billing — NET REVENUE increased by 7.8% year-over-year, from $122.04M to $131.61M.
- What is the long-term trend for NeoGenomics's client direct billing — NET REVENUE?
- Over 4 years (2021 to 2025), NeoGenomics's client direct billing — NET REVENUE has grown at a 19.7% compound annual growth rate (CAGR), from $252.62M to $518.84M.
- What does client direct billing — NET REVENUE mean?
- This metric represents the total net revenue generated from diagnostic testing services billed directly to healthcare providers, hospitals, and clinical institutions. It reflects the company's ability to capture market share within the clinical diagnostics space by establishing direct commercial relationships with ordering physicians and facilities. Growth in this segment indicates successful penetration of the clinical services market and effective management of direct-to-provider billing channels.